Abstract: A pharmaceutical composition and a health functional food composition for preventing, treating, or improving muscular diseases have licorice extract or a fraction thereof, or a compound isolated therefrom or a pharmaceutically acceptable salt thereof, as an active ingredient. The licorice extract or a fraction thereof, the compound or salt thereof induce the myoblasts proliferation and promote the differentiation into myotubes, and since the licorice extract or a fraction thereof, the compound or salt thereof has an excellent effect on regenerating damaged muscles, various muscle diseases are effectively prevented, improved or treated using the composition.

Abstract: A vehicle seat includes a fixed frame installed in a vehicle body, a rotating link connected to the fixed frame through a rotation shaft and rotating relative to the rotation shaft, a seat cushion frame having one side of a rear end portion hinge-connected to the rotating link at a first connection point to rotate the rotating link when rotating, and a seat back frame having one side of a lower end portion hinge-connected to the fixed frame at a second connection point and the other side of the lower end portion hinge-connected to the other side of the rear end portion of the seat cushion frame at a third connection point to rotate relative to the fixed frame when the seat cushion frame is rotated.

Abstract: A computing device includes at least one memory and at least one processor. The at least one processor is configured to detect a plurality of tumor cells included in one or more tumor areas (cancer areas) from a pathological slide image, determine a cell expression class of the plurality of tumor cells, based on a biomarker expression degree of the plurality of tumor cells, and generate a heatmap image for the pathological slide image, based on a result of the determining.

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

Abstract: The present invention relates to a pharmaceutical composition comprising a maple leaf extract or fraction thereof for preventing or treating a retinal disease, a method for preventing or treating a retinal disease using the pharmaceutical composition, and a food composition comprising a maple leaf extract or fraction thereof for ameliorating the symptoms of a retinal disease. The pharmaceutical composition according to the present invention, which is effective for the treatment of a retinal disease, can be used pharmaceutically as a composition for preventing or treating a retinal disease, and can also be used advantageously as a health functional food.

Abstract: A pharmaceutical composition and a health functional food composition for preventing, treating, or improving muscular diseases have licorice extract or a fraction thereof, or a compound isolated therefrom or a pharmaceutically acceptable salt thereof, as an active ingredient. The licorice extract or a fraction thereof, the compound or salt thereof induce the myoblasts proliferation and promote the differentiation into myotubes, and since the licorice extract or a fraction thereof, the compound or salt thereof has an excellent effect on regenerating damaged muscles, various muscle diseases are effectively prevented, improved or treated using the composition.

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

Abstract: The present invention relates to a pharmaceutical composition comprising a maple leaf extract or fraction thereof for preventing or treating a retinal disease, a method for preventing or treating a retinal disease using the pharmaceutical composition, and a food composition comprising a maple leaf extract or fraction thereof for ameliorating the symptoms of a retinal disease. The pharmaceutical composition according to the present invention, which is effective for the treatment of a retinal disease, can be used pharmaceutically as a composition for preventing or treating a retinal disease, and can also be used advantageously as a health functional food.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.

Abstract: The present invention relates to a novel technology for forming fine particles with a size of 0.0˜23 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

Abstract: The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

Abstract: The present invention relates to recombinant adenoviruses expressing interleukin-18 protein, and gene therapy using them. More particularly, the invention provides recombinant adenoviruses Ad.promIL-18, Ad.GMmIL-18, Ad.prohIL-18, Ad.hIL-18CPP32- and Ad.preprotrypsin.hIL-18CPP32- which are effectively capable of treating a variety of cancer cells by promoting and enhancing an immune response in vivo.

Abstract: The present invention relates to recombinant adenoviruses expressing interleukin-18 protein, and gene therapy using them. More particularly, the invention provides recombinant adenoviruses Ad.promIL-18, Ad.GMmIL-18, Ad.prohIL-18, Ad.hIL-18CPP32- and Ad.preprotrypsin.hIL-18CPP32- which are effectively capable of treating a variety of cancer cells by promoting and enhancing an immune response in vivo.

Abstract: The present invention relates to a vector comprising P972 (also referred to as Gadd45&ggr;, CR6 or OIG37) gene known as a gene producing a cell growth-inhibiting protein for the treatment of cancers, an recombinant adenovirus that encodes P972 gene in the cell, a method of producing the above adenovirus and a method for the treatment of cancers by using the above vector or adenovirus. The recombinant adenovirus of the present invention can be used in the treatment of various cancers including cervical cancer, breast cancerand colon cancer.